EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

被引：0
|
作者：
Jiang, T. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(18)30403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
129O
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [21] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Guowei Zhang
    Ruirui Cheng
    Zengli Zhang
    Tao Jiang
    Shengxiang Ren
    Zhiyong Ma
    Sha Zhao
    Caicun Zhou
    Jun Zhang
    Scientific Reports, 7
  • [22] Continued EGFR-TKIs treatment promotes the survival of elderly patients with acquired resistance to EGFR-TKIs therapy
    Wang, P.
    Zhang, D.
    Li, X. -M.
    Guo, X. -G.
    Sun, B. -J.
    Fang, X. -Q.
    Qu, G. -P.
    An, L.
    Liu, C. -T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (11) : 2450 - 2459
  • [23] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Zhang, Guowei
    Cheng, Ruirui
    Zhang, Zengli
    Jiang, Tao
    Ren, Shengxiang
    Ma, Zhiyong
    Zhao, Sha
    Zhou, Caicun
    Zhang, Jun
    SCIENTIFIC REPORTS, 2017, 7
  • [24] Efficacy of EGFR-TKIs for EGFR Mutant NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis
    Koyama, K.
    Saida, Y.
    Abe, T.
    Satokata, M.
    Mishina, Y.
    Sato, K.
    Shoji, S.
    Tanaka, T.
    Nozaki, K.
    Ichikawa, K.
    Miyabayashi, T.
    Ota, T.
    Fujimori, F.
    Ito, R.
    Kondo, R.
    Hiura, T.
    Okajima, M.
    Miura, S.
    Watanabe, S.
    Matsumoto, N.
    Tanaka, H.
    Kikuchi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2132 - S2132
  • [25] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [26] Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis
    Lv, Fangfang
    Sun, Liang
    Yang, Qiuping
    Pan, Zheng
    Zhang, Yuhua
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [27] EGFR-TKIs Combined Hydroxycamptothecin Improved Outcomes in EGFR-Mutant NSCLC Patients Who Harboring Pericardial Effusion
    Wang, X.
    Yao, J.
    Guo, R.
    Lu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S985 - S985
  • [28] Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism
    Liu, Si-Yang
    Zhou, Jia-Ying
    Li, Wen-Feng
    Sun, Hao
    Zhang, Yi-Chen
    Yan, Hong-Hong
    Chen, Zhi-Hong
    Chen, Chun-Xiang
    Ye, Jun-Yi
    Yang, Jin-Ji
    Zhou, Qing
    Zhang, Xu-Chao
    Wu, Yi-Long
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (01): : 337 - 345
  • [29] The Effect of Metformin on Survival Outcomes of Advanced EGFR-mutant NSCLC Patients Treated with EGFR TKIs in Thailand
    Saichaemchan, S.
    Kanjanavithayakul, Y.
    Prasongsook, N.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S484 - S485
  • [30] Bisphosphonates enhance effect of EGFR-TKIs in NSCLC patients with EGFR mutation and bone metastases
    Jiang, T.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2016, 27
12345